- My News
- All News
- Most Popular
OAKLAND, Calif. & FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)-- Fabric Genomics, a global computational genomics company, and TOMA Biosciences, a genomic cancer diagnostics company, announced today a partnership that will bring together premier chemistry and informatics platforms for deepened genomic analysis of cancer and delivery of clinically meaningful information for tumor profiling. The companies will co-develop an end-to-end oncology genomic testing and clinical interpretation offering for clinical laboratories. News of the partnership will be highlighted at the AACR Annual 2017 Meeting this week in Washington, D.C.
"Our platform, Fabric Enterprise™, now extends beyond hereditary disease and provides labs with robust somatic cancer analysis and reporting capabilities," said Matt Tindall, CEO of Fabric Genomics. "The goal of the collaboration is to provide labs offering cancer testing with a breakthrough assay for comprehensive analysis of all types of tumor samples—even those with limited volume and poor quality, including FFPE tissue. Our raw data-to-report platform for next-generation sequencing data analysis coupled with the TOMA OS-Seq Assay creates a seamless tumor profiling system for detection and clinical interpretation of somatic cancer variants."
"We enable laboratories around the world to detect biomarkers for the diagnosis and treatment of cancer. As a result of our partnership with Fabric Genomics, we can offer a truly end-to-end solution," said Wolfgang Daum, President and CEO of TOMA. "This system integrates TOMA's wet lab and somatic bioinformatics pipeline with the annotation and reporting platform offered by Fabric Genomics. This combined service offers clinical laboratories everything they need to conduct tumor profiling from tumor DNA to report and can be up and running and ready to begin validation in under a week."
TOMA's proprietary oligo selective sequencing (OS-Seq) technology, which contains all necessary reagents to efficiently prepare sample DNA for sequencing, was invented at Stanford University, where it continues to be used today.
About TOMA Biosciences
TOMA Biosciences Inc. is a genomics information company and the developer of the COMPASS Tumor Profiling System. COMPASS makes cancer genomics simple. The system includes everything a clinical laboratory needs to detect genomic changes in tumors, including many missed by other methods. With its core sequencing technology invented at Stanford University, TOMA Biosciences provides a comprehensive solution to prepare tumor DNA for sequencing and reveal somatic variants. The company is led by innovative scientists, clinicians and technology developers to enable clinical laboratories, hospital systems and research institutions around the world to do cancer genomics. Headquartered in Foster City, California, TOMA Biosciences is a commercial stage, private venture-backed company.
About Fabric Genomics
Fabric Genomics™ is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics' analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughput panels, exomes and whole genomes. The company can process any NGS file input (e.g., FASTQ, BAM or VCF), providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics and is headquartered in Oakland, California, with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.
Director, Global Marketing
Source: Fabric Genomics
Did you like this article?